FATE
Price:
$2.29
Market Cap:
$260.82M
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the ...[Read more]
Industry
Biotechnology
IPO Date
2013-10-01
Stock Exchange
NASDAQ
Ticker
FATE
According to Fate Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 321.89M. This represents a change of -37.10% compared to the average of 511.73M of the last 4 quarters.
The mean historical Enterprise Value of Fate Therapeutics, Inc. over the last ten years is 1.65B. The current 321.89M Enterprise Value has changed 1.85% with respect to the historical average. Over the past ten years (40 quarters), FATE's Enterprise Value was at its highest in in the June 2021 quarter at 8.22B. The Enterprise Value was at its lowest in in the December 2016 quarter at 15.49M.
Average
1.65B
Median
487.54M
Minimum
1.78M
Maximum
7.42B
Discovering the peaks and valleys of Fate Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 10.13%
Maximum Annual Enterprise Value = 7.42B
Minimum Annual Increase = -580.50%
Minimum Annual Enterprise Value = 1.78M
Year | Enterprise Value | Change |
---|---|---|
2023 | 429.72M | -58.07% |
2022 | 1.02B | -81.45% |
2021 | 5.52B | -25.55% |
2020 | 7.42B | 488.24% |
2019 | 1.26B | 131.33% |
2018 | 545.36M | 199.05% |
2017 | 182.37M | 10.13% |
2016 | 1.78M | -95.47% |
2015 | 39.31M | -46.44% |
2014 | 73.40M | -580.50% |
The current Enterprise Value of Fate Therapeutics, Inc. (FATE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
2.33B
5-year avg
3.13B
10-year avg
1.65B
Fate Therapeutics, Inc.’s Enterprise Value is greater than Atara Biotherapeutics, Inc. (54.85M), less than Sana Biotechnology, Inc. (551.82M), greater than Caribou Biosciences, Inc. (177.59M), less than Arcus Biosciences, Inc. (1.20B), less than Intellia Therapeutics, Inc. (1.44B), greater than Editas Medicine, Inc. (144.07M), less than CRISPR Therapeutics AG (4.09B), less than Verve Therapeutics, Inc. (323.17M), greater than Theseus Pharmaceuticals, Inc. (138.26M), greater than aTyr Pharma, Inc. (138.44M), less than Relay Therapeutics, Inc. (692.53M), greater than Century Therapeutics, Inc. (104.89M), less than Blueprint Medicines Corporation (6.36B), less than Beam Therapeutics Inc. (2.01B), less than Prime Medicine, Inc. (342.99M),
Company | Enterprise Value | Market cap |
---|---|---|
54.85M | $66.06M | |
551.82M | $582.73M | |
177.59M | $182.92M | |
1.20B | $1.35B | |
1.44B | $1.46B | |
144.07M | $201.42M | |
4.09B | $4.09B | |
323.17M | $410.62M | |
138.26M | $181.50M | |
138.44M | $131.12M | |
692.53M | $795.07M | |
104.89M | $102.89M | |
6.36B | $5.98B | |
2.01B | $2.07B | |
342.99M | $419.71M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Fate Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Fate Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Fate Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Fate Therapeutics, Inc. (FATE)?
What is the 3-year average Enterprise Value for Fate Therapeutics, Inc. (FATE)?
What is the 5-year average Enterprise Value for Fate Therapeutics, Inc. (FATE)?
How does the current Enterprise Value for Fate Therapeutics, Inc. (FATE) compare to its historical average?